Kielb, S J <br/><br/>
Functional p53 mutation as a molecular determinant of paclitaxel and gemcitabine susceptibility in human bladder cancer.  [electronic resource] 

 -  The Journal of urology  Aug 2001 
 - 482-7 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S. 
<br/><br/><label>ISSN: </label>0022-5347 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antimetabolites, Antineoplastic--pharmacology<br/>Antineoplastic Agents, Phytogenic--pharmacology<br/>Blotting, Western<br/>Cell Death<br/>Cell Line<br/>Deoxycytidine--analogs & derivatives<br/>Drug Screening Assays, Antitumor<br/>Humans<br/>Immunohistochemistry<br/>Mutation<br/>Paclitaxel--pharmacology<br/>Transfection<br/>Tumor Cells, Cultured<br/>Tumor Suppressor Protein p53--genetics<br/>Urinary Bladder Neoplasms--drug therapy<br/>Gemcitabine